Clinical benefits of a new piperidine-class AChE inhibitor
- 12 April 1999
- journal article
- review article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 9, S69-S77
- https://doi.org/10.1016/s0924-977x(98)00047-9
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- P.4.005 Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate alzheimer's diseaseEuropean Neuropsychopharmacology, 1997
- Neurochemical Correlates of Dementia Severity in Alzheimer's Disease: Relative Importance of the Cholinergic DeficitsJournal of Neurochemistry, 1995
- Secreted acetylcholinesterase: non-classical aspects of a classical enzymeTrends in Neurosciences, 1992
- A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study GroupJAMA, 1992
- A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's DiseaseNew England Journal of Medicine, 1992
- Mild senile dementia of the Alzheimer type. 4. Evaluation of interventionAnnals of Neurology, 1992
- Tetrahydroaminoacridine–Lecithin Combination Treatment in Patients with Intermediate-Stage Alzheimer's DiseaseNew England Journal of Medicine, 1990
- Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Francais d'Etude de la Tetrahydroaminoacridine.BMJ, 1990
- A New Clinical Scale for the Staging of DementiaThe British Journal of Psychiatry, 1982
- “Mini-mental state”Journal of Psychiatric Research, 1975